• You might be wondering whether Amgen at around US$329 is offering fair value right now or if the current price is out of line with what the business looks worth.
• The stock has been fairly steady year to date with a 0.4% return, although the recent 7 day and 30 day returns of 5.0% and 3.2% declines sit against a stronger 24.7% return over the past year and 52.7% to 55.6% returns across the past 3 to 5 years.
• Recent headlines around Amgen have focused on its position in large cap biotech, product pipeline developments and the broader sector's sentiment. These factors can quickly influence how investors think about risk and potential. These kinds of updates often sit in the background when prices move, even if they do not all make front page news for general investors.
• Simply Wall St currently gives Amgen a value score of 4 out of 6. The rest of this article will walk through the key valuation approaches behind that score and then finish with a broader way to think about what the stock could be worth.

Approach 1: Amgen Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting its future cash flows and then discounting those amounts back to today using a required return. It focuses on the cash the company is expected to generate for shareholders over time.

Amgen’s latest twelve month Free Cash Flow is about $9.1b. Analysts have provided forecasts for several years ahead, and Simply Wall St extends those estimates further, using a 2 Stage Free Cash Flow to Equity model. On this basis, projected Free Cash Flow for 2030 is $16.7b, with intermediate years between 2026 and 2035 ranging from about $12.7b to $20.8b in nominal terms before discounting.

After discounting these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $670 per share. Compared with the recent share price around $329, this implies the stock is 50.9% undervalued according to this particular DCF set up.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Amgen is undervalued by 50.9%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Amgen Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it directly links what you pay for the stock to the earnings it is currently generating. It gives you a quick sense of how many dollars investors are willing to pay today for each dollar of earnings.

What counts as a “normal” P/E depends heavily on growth expectations and risk. Higher expected earnings growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower multiple being more reasonable.

Amgen trades on a P/E of about 22.8x, compared with the Biotechs industry average of roughly 17.8x and a peer group average around 40.1x. Simply Wall St’s proprietary Fair Ratio for Amgen is 25.3x. This Fair Ratio is designed to reflect the P/E you might expect given factors such as the company’s earnings growth profile, industry, profit margins, market capitalization and specific risks.

Because it blends these company specific drivers, the Fair Ratio is intended to be more tailored than a simple comparison with peers or the broad industry. With Amgen’s current P/E of 22.8x sitting below the Fair Ratio of 25.3x, the stock screens as undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Amgen Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple way for you to attach a story about Amgen to the numbers you think are reasonable for its future revenue, earnings, margins and fair value. You can then see how that stacks up against the current price on Simply Wall St’s Community page, where Narratives are used by millions of investors and update automatically as new news or earnings arrive. This means you can compare very different viewpoints, such as a cautious Amgen Narrative that leans toward a Fair Value around US$243 based on flatter revenue and lower margins, or a more optimistic Amgen Narrative closer to US$432 built on assumptions of stronger growth and higher profitability, and then decide for yourself whether the market price looks high, low or about right for the story you actually believe.

For Amgen however we will make it really easy for you with previews of two leading Amgen Narratives:

Start with the bullish one if you want to see what a more optimistic outcome for the stock could look like in numbers.

Fair value: US$432.00

Implied undervaluation vs last close: 23.8%

Revenue growth assumption: 6.52%

• Assumes Amgen continues to build on its autoimmune, cardiovascular and obesity pipeline to support higher future cash generation.
• Factors in the use of AI in R&D, broader global reach and M&A capacity as supports for higher earnings and margins over time.
• Flags policy risk, patent expiries, biosimilar competition, higher R&D spend and acquisition execution as key pressures that could challenge this view.

If you lean more cautious on trial risk, pricing pressure or the recent share price move, compare that with the bearish setup.

Fair value: US$243.49

Implied overvaluation vs last close: 35.1%

Revenue growth assumption: 0.07%

• Emphasises reliance on aging therapies, patent cliffs and rising biosimilar competition as potential drags on revenue and margins.
• Highlights drug pricing reform, value based care and integration of large acquisitions as factors that could weigh on profitability.
• Accepts that the pipeline and secular healthcare trends are supportive, but questions whether this is enough to offset pricing and competition risks at the current share price.

Both narratives use the same underlying company data but tell very different stories about where Amgen could be heading. The next step is to decide which story is closer to your own view of the risks and opportunities and then see how that lines up with the current market price by reviewing the full Community Narratives on Simply Wall St. See what the community is saying about Amgen

Do you think there's more to the story for Amgen? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.